cfDNA Quantification

 As a biomarker for cancer management

cfDNA Test for Monitoring Treatment Response & Disease Progression.

Directly Quantify cfDNA. No DNA extraction or amplification needed.

Ideal for Research and Clinical Studies.

Minimal sample amount required: only 10 uL plasma needed.

cfDNA Quantification

 As a biomarker for cancer management

cfDNA test for monitoring treatment response & disease progression.

Directly quantify cfDNA. No DNA extraction or amplification needed.

Ideal for research and clinical studies.

Minimal sample amount required: only 10 uL plasma needed.

QuantiDNA™ Direct cfDNA Test 

Liquid biopsy has become an essential tool for cancer diagnostics and cfDNA (cell-free DNA), including ctDNA (circulating tumor DNA) is an essential biomarker for cancer characterization, such as measurement of cfDNA concentration, mutation, and methylation analysis of ctDNA. Since ctDNA is only a small proportion of cfDNA, direct ctDNA concentration measurement is not easy unless the mutation nature of ctDNA is known. Since the cfDNA is proportional to the ctDNA level, measuring ctDNA can be done by directly measuring the cfDNA. cfDNA quantification has been approved as a biomarker or potential biomarker in many research papers.

However, there is no standard method for quantification of cfDNA. Although qPCR and fluorescent dye-binding methods are often used, most of the studies using these methods need to extract DNA for cfDNA concentration measurement.

DiaCarta has developed a direct cfDNA quantification method that eliminates sample loss caused by DNA extraction. To reduce detection variation, the cfDNA is directly quantified by signal amplification, not target amplification.

cfDNA quantification has been used in the areas including, but not limited to:

  • Comparison between healthy individuals and people with cancer or other diseases
  • Comparison between the early-stage/local cancer patients and patients with metastatic cancer
  • Comparison between patients before and after surgery
  • Prognosis biomarkers for different stages of cancer patients
  • Prognosis biomarkers after different treatments
  • Therapy responses during or after therapies
  • ctDNA quantification in MRD (molecular residual disease)

Special Deal!

To help set up our cfDNA quantification method in your lab, we offer you the following benefits. Contact us today as the offer still lasts!

20%

Discount

when buying 20 kits (600 cfDNA quantification samples)

FREE

Instruments

Buy 20 kits (600 cfDNA quantification samples), get a FREE luminometer and a FREE thermal shaker incubator, while supplies last

Resources

Need Help?

Call us: +1 (800) 246-8878

Email us: information@diacarta.com

Contact Us!

Ready to Subscribe and Learn?

Register and Learn!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

X